| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| TCR2 THERAPEUTICS INC. | Chief Scientific Officer | Common Stock | 45,850 | $78,862 | $1.72 | 09 Dec 2021 | Direct |
| TCR2 THERAPEUTICS INC. | Chief Scientific Officer | Stock Option (Right to Buy) | 100,000 | $74,000 | $0.7400 | 09 Dec 2021 | Direct |
| Alaunos Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 12,800 | 06 Jun 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TCRT | Alaunos Therapeutics, Inc. | 06 Jun 2024 | 1 | $0 | 4 | Director | 10 Jun 2024, 17:00 |
| TCRT | Alaunos Therapeutics, Inc. | 06 Jun 2023 | 1 | $0 | 4 | Director | 08 Jun 2023, 17:24 |
| TCRT | Alaunos Therapeutics, Inc. | 30 Mar 2023 | 2 | $0 | 4 | Director | 19 Apr 2023, 17:00 |
| TCRT | Alaunos Therapeutics, Inc. | 30 Mar 2023 | 0 | $0 | 3 | Director | 19 Apr 2023, 16:30 |
| /report/000120919121069032-hofmeister-robert-2021-12-09 | TCR2 THERAPEUTICS INC. | 09 Dec 2021 | 1 | $0 | 4 | Chief Scientific Officer | 10 Dec 2021, 15:30 |